Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Genistein. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 6/20 | 0.94 |
| ▸ | ESR1 known ✓ | P03372 | 3/20 | 0.94 |
| ▸ | ESR2 known ✓ | Q92731 | 3/20 | 0.94 |
| ▸ | EGFR known ✓ | P00533 | 3/20 | 0.94 |
| ▸ | ABL1 known ✓ | P00519 | 2/20 | 0.94 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 2/20 | 0.94 |
| ▸ | ODC1 known ✓ | P11926 | 1/20 | 0.94 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.94 |
| ▸ | DPP4 known ✓ | P27487 | 1/20 | 0.94 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.94 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.94 |
| ▸ | ADORA2A known ✓ | P29274 | 1/20 | 0.94 |
| ▸ | ADORA1 known ✓ | P30542 | 1/20 | 0.94 |
| ▸ | SYK known ✓ | P43405 | 1/20 | 0.94 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.94 |
| ▸ | MAPT | P10636 | 7/20 | 0.94 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.94 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.94 |
| ▸ | RAB9A | P51151 | 7/20 | 0.94 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Genistein SCHEMBL551801 | 0.98 | MAPT (0.97) | MAPTSMN1; SMN2ALDH1A1RAB9AMEN1 | |
| Genistein SCHEMBL551449 | 0.98 | MAPT (0.97) | MAPTSMN1; SMN2ALDH1A1RAB9AMEN1 | |
| Genistein SCHEMBL29586312 | 0.97 | MAPT (0.94) | MAPTSMN1; SMN2ALDH1A1RAB9AMEN1 | |
| Genistein SCHEMBL29586147 | 0.97 | MAPT (0.94) | MAPTSMN1; SMN2ALDH1A1RAB9AMEN1 | |
| Genistein SCHEMBL552594 | 0.97 | MAPT (0.94) | MAPTSMN1; SMN2ALDH1A1RAB9AMEN1 | |
| Genistein SCHEMBL29586070 | 0.97 | MAPT (0.94) | MAPTSMN1; SMN2ALDH1A1RAB9AMEN1 | |
| Genistein SCHEMBL29352944 | 0.97 | MAPT (1.00) | MAPTSMN1; SMN2ALDH1A1RAB9AMEN1 | |
| Genistein SCHEMBL554056 | 0.97 | MAPT (1.00) | MAPTSMN1; SMN2ALDH1A1RAB9AMEN1 | |
| Genistein SCHEMBL19166 | 0.97 | MAPT (1.00) | MAPTSMN1; SMN2ALDH1A1RAB9AMEN1 | |
| Genistein SCHEMBL38650814 | 0.95 | MAPT (0.97) | MAPTSMN1; SMN2ALDH1A1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113209068-A | Dosage forms and therapeutic uses of L-4-chlorokynurenine | 维斯塔津治疗公司 | 2021-08-06 | — | — | CN | disclosed |
| CN-113116877-A | Dosage forms and therapeutic uses of L-4-chlorokynurenine | 维斯塔津治疗公司 | 2021-07-16 | — | — | CN | disclosed |
| CN-112933073-A | Dosage forms and therapeutic uses of L-4-chlorokynurenine | 维斯塔津治疗公司 | 2021-06-11 | — | — | CN | disclosed |
| US-9492425-B2 | Crystalline forms of genistein | AXCENTUA PHARMACEUTICALS AB (SE) | 2016-11-15 | — | — | US | disclosed |
| EP-2373326-B1 | CRYSTALLINE FORMS OF GENISTEIN | AXCENTUA PHARMACEUTUCALS AB (SE) | 2016-03-09 | — | — | EP | disclosed |
| CN-105073108-A | Dosage forms and therapeutic uses of l-4-chlorokynurenine | VISTAGEN THERAPEUTICS INC | 2015-11-18 | — | — | CN | disclosed |
| US-20150290166-A1 | CRYSTALLINE FORMS OF GENISTEIN | AXCENTUA PHARMACEUTICALS AB (SE) | 2015-10-15 | — | — | US | disclosed |
| US-9012495-B2 | Crystalline forms of genistein | AXCENTUA PHARMACEUTICALS AB (SE) | 2015-04-21 | — | — | US | disclosed |
| US-20120035253-A1 | CRYSTALLINE FORMS OF GENISTEIN | AXCENTUA PHARMACEUTICALS AB (SE) | 2012-02-09 | — | — | US | disclosed |
| CN-102292097-A | Crystalline forms of genistein | — | 2011-12-21 | — | — | CN | disclosed |
| EP-2373326-A1 | CRYSTALLINE FORMS OF GENISTEIN | Axcentua Pharmaceutucals AB (SE) | 2011-10-12 | — | — | EP | disclosed |
| US-7863325-B2 | Crystalline genistein sodium salt dihydrate | AXCENTUA PHARMACEUTICALS AB (SE) | 2011-01-04 | — | — | US | disclosed |
| US-20100160426-A1 | CRYSTALLINE GENISTEIN SODIUM SALT DIHYDRATE | AXCENTUA PHARAMACEUTICALS AB (SE) | 2010-06-24 | — | — | US | disclosed |
| WO-2010068861-A1 | CRYSTALLINE FORMS OF GENISTEIN | AXCENTUA PHARMACEUTUCALS AB (SE) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160426-A1 | CRYSTALLINE GENISTEIN SODIUM SALT DIHYDRATE | SHBG, GLS, CDC42 | MEN1 1731/4885ESR1 417/4885ESR2 896/4885 |
| US-20150290166-A1 | CRYSTALLINE FORMS OF GENISTEIN | SHBG, GLS, KLK3 | MEN1 696/4885ESR1 269/4885ESR2 778/4885 |
| US-20120035253-A1 | CRYSTALLINE FORMS OF GENISTEIN | SHBG, GLS, KLK3 | MEN1 696/4885ESR1 269/4885ESR2 778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.